VGXI Partners With BioMAP Consortium To Accelerate Drug Discovery

VGXI Inc., a leading contract development and manufacturing organization (CDMO) specializing in nucleic acid-based biopharmaceuticals, has officially become a member of the Biopharmaceutical Manufacturing Preparedness (BioMap) Consortium. This consortium aims to strengthen the United States' biopharmaceutical production capabilities and enhance bio-manufacturing output.

The BioMap Consortium is backed by the Biomedical Advanced Research and Development Authority (BARDA) through its Pharmaceutical Countermeasure Infrastructure (PCI) Division and BioMap Branch.

By joining this prestigious group of over 200 member companies, VGXI commits to bolstering the nation’s ability to manufacture essential biopharmaceutical products and materials. This ensures that therapies and countermeasures can be swiftly made available to civilian populations when needed. With over 20 years of expertise in plasmid DNA manufacturing, VGXI boasts the world’s largest plasmid production capacity at 4000 liters, offering unmatched flexibility and scalability to support the development of next-generation therapeutics at all stages—from early research to full-scale commercial production.

Young Park, CEO at VGXI, stated, "We are proud to be a part of the BioMap Consortium. Our demonstrated history of manufacturing solutions for public health allows VGXI to be a valuable contributor to this consortium and to support our fellow members and US-based biomanufacturing to address health-related threats to the nation's public health.”